Saket Reddy on Twitter
twitter.com/saketreddy/status/1676266917328478208
1 Users
0 Comments
6 Highlights
0 Notes
Tags
Top Highlights
SYNGENE to acquire multi-modal facility from Stelis Biopharma Ltd,
adding 20,000 liters of installed biologics drug substance manufacturing capacity,
fill-finish unit for a gross consideration of 702Cr.
monoclonal antibodies
Syngene will further invest up to INR 100 Crores (US$12Mn) to repurpose and revalidate the facility.
Expect this facility to be operational in 2024,
Ready to highlight and find good content?
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.